NVO
New price target, same cautious vibe
Jefferies just nudged Novo Nordisk’s price target down to DKK270 from DKK275 and left the stock at Hold. Not exactly a dramatic plot twist, but the message is pretty clear: the broker sees more fog than fireworks heading into first-quarter results.
Why the market cares
The concern isn’t that Novo has suddenly lost its magic trick. It’s that the GLP-1 party is getting crowded, pricing is getting squishier, and the shiny new oral Wegovy pill may end up stealing sales from the old cash cow instead of creating a whole new buffet line.
That’s the kind of thing investors hate because it turns a clean growth story into a messy spreadsheet debate. And when the market starts wondering whether a new launch expands the franchise or just shuffles revenue around like musical chairs, the multiple can get cranky fast.
Big picture
Novo still has long-term pipeline appeal, but near-term expectations are clearly under pressure. Translation: the company isn’t broken, but the easy-mode part of the story may be over for now.